TPST

Tempest Therapeutics, Inc.

There isn't enough reported data to score TPST yet.

TPST Fundamentals

MetricStatus
Unavailable
Under pressure
Unavailable
Unavailable

TPST's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.

TPST PE Valuation

TPST has no meaningful PE right now: it lost money over the past year.

TPST Forward outlook

There aren't enough analyst estimates for TPST to show an outlook.

TPST Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $0.38 on Nov 12.

There is not enough scenario data to assess TPST's risk to reward.

TPST Earnings Per Share

Q3 2023: $-26.39Q4 2023: $-24.83Q1 2024: $-22.36Q2 2024: $-20.80Q3 2024: $-19.89Q4 2024: $-19.50Q1 2025: $-17.98Q2 2025: $-14.59Q3 2025: $-10.05
Q3 2023: $-26.39Q4 2023: $-24.83Q1 2024: $-22.36Q2 2024: $-20.80Q3 2024: $-19.89Q4 2024: $-19.50Q1 2025: $-17.98Q2 2025: $-14.59Q3 2025: $-10.05
QuarterTTM EPSYoY
Q3 2025-$10.05+$9.84
Q2 2025-$14.59+$6.21
Q1 2025-$17.98+$4.38
Q4 2024-$19.50+$5.33
Q3 2024-$19.89+$6.50
Q2 2024-$20.80+$7.93
Q1 2024-$22.36+$9.62
Q4 2023-$24.83+$15.34

TPST is still losing money, but far less than before: $10.05 per share over the past year, against $633.75 at its worst in late 2019.

TPST Quarterly Revenue

Q3 2023: --Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: --Q4 2024: --Q1 2025: --Q2 2025: --Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --
Q3 2023: --Q4 2023: --Q1 2024: --Q2 2024: --Q3 2024: --Q4 2024: --Q1 2025: --Q2 2025: --Q3 2025: --Q4 2025: --Q1 2026: --Q2 2026: --

TPST Free Cash Flow

Q3 2023: −$6MQ4 2023: −$6MQ1 2024: −$7MQ2 2024: −$6MQ3 2024: −$10MQ4 2024: −$10MQ1 2025: −$8MQ2 2025: −$8MQ3 2025: −$7MQ4 2025: −$4MQ1 2026: −$8MQ2 2026: −$3M
Q3 2023: −$6MQ4 2023: −$6MQ1 2024: −$7MQ2 2024: −$6MQ3 2024: −$10MQ4 2024: −$10MQ1 2025: −$8MQ2 2025: −$8MQ3 2025: −$7MQ4 2025: −$4MQ1 2026: −$8MQ2 2026: −$3M
QuarterFree cash flowYoY
Q2 2026-$2.8M+$5.7M
Q1 2026-$7.6M+$438K
Q4 2025-$3.6M+$6.6M
Q3 2025-$6.8M+$3.4M
Q2 2025-$8.4M-$2.7M
Q1 2025-$8M-$682K
Q4 2024-$10.2M-$4M
Q3 2024-$10.2M-$3.7M

TPST has burned cash in almost every quarter: −$21M over the past year, against −$37M the year before.

TPST Total Shares

Q3 2023: 1MQ1 2024: 2MQ2 2024: 2MQ3 2024: 2MQ4 2024: 2MQ1 2025: 3MQ2 2025: 4MQ3 2025: 4MQ1 2026: 11MQ2 2026: 15M
Q3 2023: 1MQ1 2024: 2MQ2 2024: 2MQ3 2024: 2MQ4 2024: 2MQ1 2025: 3MQ2 2025: 4MQ3 2025: 4MQ1 2026: 11MQ2 2026: 15M
PeriodChange %Net change
Quarterly+39%+4.3M shares
1 year+343%+11.8M shares
3 years+1614%+14.3M shares
5 years+15525%+15.1M shares

TPST has 15M diluted shares, up 343% from a year ago.

TPST Net Leverage

TPST's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

TPST Weekly Momentum

MetricValueStatus
RSI23.3Oversold
Stochastic1.8Oversold

TPST's weekly RSI is 23 (oversold) and its Stochastic is 2 (oversold).

TPST PE vs Healthcare Sector

TPST has no meaningful PE right now: it lost money over the past year.

TPST Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$0.6037% below
20 week MA$0.8254% below
50 week MA$1.6577% below
100 week MA$5.3393% below
200 week MA$17.098% below

TPST is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.

TPST Yearly ROI

YearStart priceEnd priceROI
2020$1,339.7$442.7-67%
2021$442.7$79.3-82%
2022$79.3$16.5-79%
2023$16.5$57.2+246%
2024$57.2$10.9-81%
2025$10.9$2.99-73%
2026 YTD$2.99$0.38-87%

TPST's yearly returns have swung widely, from +246% in 2023 to −82% in 2021. It's down 87% so far in 2026.

Give your agent the market.

Get API key